Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 10/20 | 0.64 |
| ▸ | LMNA | P02545 | 7/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 2/20 | 0.50 |
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286367 | 0.83 | LMNA (0.67) | KMT2AMAPTLMNATP53MEN1 | |
| Calcium SCHEMBL29917796 | 0.82 | LMNA (0.65) | KMT2AMAPTLMNATP53MEN1 | |
| SCHEMBL21114783 | 0.82 | KMT2A (1.00) | KMT2ARAD52MAPTLMNATP53 | |
| SCHEMBL7984120 | 0.82 | PARP1 (0.57) | KMT2ARAD52MAPTLMNATP53 | |
| SCHEMBL8316089 | 0.81 | MAPKAPK2 (0.55) | KMT2AMAPTLMNATP53MEN1 | |
| Hydrochloric Acid SCHEMBL18345596 | 0.81 | KMT2A (0.97) | KMT2ARAD52MAPTLMNATP53 | |
| SCHEMBL4279959 | 0.80 | LMNA (0.67) | KMT2AMAPTLMNATP53MEN1 | |
| SCHEMBL30667611 | 0.79 | PARP1 (0.70) | KMT2ARAD52MAPTLMNATP53 | |
| SCHEMBL7412220 | 0.79 | KMT2A (0.60) | KMT2ARAD52MAPTLMNATP53 | |
| SCHEMBL13362016 | 0.78 | KMT2A (0.64) | KMT2AMAPTLMNATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | ALLERGAN SALES, LLC | 2012-05-24 | — | — | US | disclosed |
| US-8129519-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | ALLERGAN SALES, LLC | 2012-03-06 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| US-4122089-A | Aminothiofluoran compounds, process for the production thereof, and recording elements containing the same | SANKIO CHEMICAL CO., LTD. (JP) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | KMT2A 4484/4885RAD52 3121/4885MAPT 3945/4885 |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | KMT2A 4484/4885RAD52 3121/4885MAPT 3945/4885 |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | WNT1, CTNND1, CTNNB1 | KMT2A 4484/4885RAD52 3121/4885MAPT 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.